Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Molecular and Cellular Endocrinology

• Publication date

  2009-01-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.mce.2008.11.018PMID 19041364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind Placebo- Controlled Trial.

  2008influential reference
• Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-daily Human GLP-1 Analog, Compared with Insulin Glargine: All as Add-on to Metformin and a Sulfonylurea in Type 2 Diabetes.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.

  2007cited by this paper
• Mechanisms of action of glucagon-like peptide 1 in the pancreas.

  2007cited by this paper
• Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not

  2007cited by this paper
• Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

  2004cited by this paper
• One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

  2004cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes

  2003cited by this paper
• Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism.

  2002cited by this paper
• Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats.

  2000cited by this paper
• Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

  2000cited by this paper
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

  2000cited by this paper
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

  2000cited by this paper
• Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A.

  1999cited by this paper
• Glucagon-Like Peptide 1 Elevates Cytosolic Calcium in Pancreaticβ -Cells Independently of Protein Kinase A1.

  1999cited by this paper
• Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

  1997cited by this paper
• Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.

  1992cited by this paper
• Induction of glucose competence in pancreatic beta cells by glucagon-like peptide-1(7-37).

  1992cited by this paper
• Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

  1987cited by this paper
• Hamster preproglucagon contains the sequence of glucagon and two related peptides

  1983cited by this paper

• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025cites this paper
• Albumin-based delivery systems: Recent advances, challenges, and opportunities.

  2025cites this paper
• Harnessing mitochondrial biogenesis to combat acute kidney injury: Current insights and futuredirections

  2025cites this paper
• Engineering a high‐throughput clone for industrial‐scale production of long‐acting GLP‐1 analogue with retained bio‐efficacy

  2025cites this paper
• Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment

  2025cites this paper
• Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review

  2025cites this paper
• Targeting neutrophil extracellular traps: A novel strategy in hematologic malignancies.

  2024cites this paper
• Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study

  2024cites this paper
• Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity

  2024cites this paper
• Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?

  2023cites this paper
• GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

  2023cites this paper
• Uncovering hidden therapeutic indications through drug repurposing with graph neural networks and heterogeneous data

  2023cites this paper
• A Spectroscopic and Molecular Dynamics Study on the Aggregation Properties of a Lipopeptide Analogue of Liraglutide, a Therapeutic Peptide against Diabetes Type 2

  2023cites this paper
• A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.

  2023cites this paper
• Adipose tissue, systematic inflammation, and neurodegenerative diseases

  2022cites this paper
• Peptide mediated therapy in fibrosis: Mechanisms, advances and prospects.

  2022cites this paper
• Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability

  2022cites this paper
• Direct visualization of glucagon‐like peptide‐1 secretion by fluorescent fusion proteins

  2022cites this paper
• Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish

  2021cites this paper
• MultiPep: a hierarchical deep learning approach for multi-label classification of peptide bioactivities

  2021cites this paper
• Copper(II) Lysinate and Pseudoproline Assistance in the Convergent Synthesis of the GLP-1 Receptor Agonists Liraglutide and Semaglutide

  2021cites this paper
• In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs

  2021cites this paper
• Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems.

  2021cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2021cites this paper
• The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride

  2020cites this paper
• UPLC-MS/MS Determination of GLP-1 Analogue, Liraglutide A Bioactive Peptide in Human Plasma : Waters

  2020cites this paper
• A brief review on newer Glucagon like Peptide-1 analogues

  2020cites this paper
• Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome

  2020cites this paper
• Incretin therapy for diabetes mellitus type 2.

  2019cites this paper
• Pharmacotherapy of Obesity: Limits and Perspectives

  2019cites this paper
• Liraglutide therapy in a prediabetic state: Rethinking the evidence.

  2019cites this paper
• The spatiotemporal control of signalling and trafficking of the GLP-1R

  2019cites this paper
• Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.

  2019cites this paper
• Biomarkers associated with glycaemic control, comorbidity and response to GLP-1 analogue therapy

  2018cites this paper
• Battle of GLP-1 delivery technologies.

  2018cites this paper
• Clinical pharmacology of glucagon-like peptide-1 receptor agonists

  2018cites this paper
• Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway

  2018cites this paper
• Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways

  2018cites this paper
• Antidiabetic Effect of Abextide, a Long‐Acting Exendin‐4 Analogue in Cynomolgus Monkeys

  2018cites this paper
• Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.

  2017cites this paper
• UHPLC-MS/MS DETERMINATION OF GLP-1 ANALOGUE, LIRAGLUTIDE A BIOACTIVE PEPTIDE IN HUMAN PLASMA

  2017cites this paper
• To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children

  2017cites this paper
• Herzinsuffizienz und Diabetes

  2017cites this paper
• Diabetes Mellitus and Heart Failure.

  2017cites this paper
• Liraglutide

  2017cites this paper
• Diabetes Mellitus and Heart Failure.

  2017cites this paper
• The effects of GLP-1 analogues on pre-diabetes of the children

  2017cites this paper
• GLP-1 nanomedicine alleviates gut inflammation.

  2017cites this paper
• Therapeutische Strategien unter Berücksichtigung aktueller Studien

  2017cites this paper
• Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.

  2017cites this paper
• Solution behaviour of Human Serum Albumin and GLP-1variants

  2016cites this paper
• Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients

  2016cites this paper
• Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance.

  2016cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2016cites this paper
• Hyperglycemic and Hypoglycemic Drugs

  2016cites this paper
• Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes

  2016cites this paper
• GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator

  2016cites this paper
• Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro

  2016cites this paper
• Long-term effects of weight-reducing diets in people with hypertension.

  2016cites this paper
• Pratique de prescription du liraglutide VICTOZA®. Étude de cohorte au sein du service d’endocrinologie et de maladies métaboliques au CHU de Rouen

  2015cites this paper
• Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations.

  2015cites this paper
• Triblock peptide-linker-lipid molecular design improves potency of peptide ligands targeting family B G protein-coupled receptors.

  2015cites this paper
• The Replacement of Phe28 by Ser Enhances the Stability of the GLP-1 Analog During Fermentation

  2015cites this paper
• Positive effects of GLP‐1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes

  2015cites this paper
• The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

  2014influential citation
• GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes

  2014cites this paper
• The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide

  2014cites this paper
• Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy

  2014cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

  2014cites this paper
• Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

  2014cites this paper
• A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: a glucagon-like peptide-1 analog.

  2014influential citation
• Protein Aggregation in Pharmaceutical Biotechnology

  2014cites this paper
• Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.

  2013cites this paper
• Liver imaging with a novel hepatitis B surface protein derived SPECT-tracer.

  2013cites this paper
• (Val8)GLP‐1‐Glu‐PAL: a GLP‐1 Agonist That Improves Hippocampal Neurogenesis, Glucose Homeostasis, and β‐Cell Function in High‐Fat‐Fed Mice

  2013cites this paper
• Peptide lipidation stabilizes structure to enhance biological function.

  2013cites this paper
• Structural Aspects of Gut Peptides with Therapeutic Potential for Type 2 Diabetes

  2013cites this paper
• Long-term effectiveness and safety of liraglutide in clinical practice.

  2013cites this paper
• Liraglutide for the Treatment of Type 2 Diabetes: A Clinical Update

  2013influential citation
• GLP-1R, a novel receptor in platelets, and the use of liraglutide in the treatment of obesity in women with PCOS

  2013cites this paper
• Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells

  2013cites this paper
• Untersuchung der Effekte des GLP-1 Systems auf Komponenten des Metabolischen Syndrom in vivo

  2013cites this paper
• Peptide-based delivery to bone.

  2012cites this paper
• The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

  2012cites this paper
• South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan

  2012cites this paper
• Roles of Glucagon‐Like Peptide and Glucose‐Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration

  2012cites this paper
• Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?

  2012cites this paper
• Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus

  2012cites this paper
• Evolving Treatment Strategies for the Management of Type 2 Diabetes

  2012cites this paper
• Chapter 3 - Pathogenesis of Type 2 Diabetes—A Comprehensive Analysis

  2012cites this paper
• Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.

  2012cites this paper
• Liraglutide: once‐daily GLP‐1 agonist for the treatment of type 2 diabetes

  2011cites this paper
• Charge inversion at position 68 of the glucagon and glucagon‐like peptide‐1 receptors supports selectivity in hormone action

  2011cites this paper
• [Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system].

  2011influential citation
• Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

  2011cites this paper
• Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

  2011cites this paper
• Advances in the treatment of type 2 diabetes mellitus.

  2011cites this paper
• Obesity – an indication for GLP‐1 treatment? Obesity pathophysiology and GLP‐1 treatment potential

  2011cites this paper
• Review of the therapeutic uses of liraglutide.

  2011cites this paper
• Huisgen Cycloaddition in Peptidomimetic Chemistry

  2011cites this paper